Foresee Pharmaceuticals

Specialty/oral small-molecule pharma

6576 · TPEx · Taiwan

Public Market Listing

6576TPEx

TPEx primary exchange listing

Live quotes, historical charts, and market capitalization for Foresee Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
ALDH2Small molecule
Pulmonary Hypertension Associated with Interstitial Lung Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
MirivadelgatPhase 2Group 3 Pulmonary Hypertension
Est. primary completion 2028-02 · NCT06475781 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3————report ↗